Rice Hall James & Associates LLC Invests $719,000 in AtriCure, Inc. $ATRC

Rice Hall James & Associates LLC acquired a new stake in AtriCure, Inc. (NASDAQ:ATRC) in the first quarter, Holdings Channel reports. The fund acquired 25,210 shares of the medical device company’s stock, valued at approximately $719,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of ATRC. Smartleaf Asset Management LLC grew its position in AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the period. Scotia Capital Inc. raised its holdings in AtriCure by 1.2% during the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock worth $1,328,000 after buying an additional 457 shares during the last quarter. ProShare Advisors LLC raised its holdings in AtriCure by 6.6% during the fourth quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock worth $349,000 after buying an additional 543 shares during the last quarter. Captrust Financial Advisors lifted its stake in shares of AtriCure by 7.9% in the fourth quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock valued at $314,000 after buying an additional 579 shares in the last quarter. Finally, Mackenzie Financial Corp lifted its stake in shares of AtriCure by 5.3% in the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock valued at $545,000 after buying an additional 683 shares in the last quarter. Institutional investors own 99.11% of the company’s stock.

AtriCure Price Performance

Shares of NASDAQ:ATRC opened at $35.04 on Monday. The company has a quick ratio of 3.18, a current ratio of 4.29 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $1.77 billion, a PE ratio of 166.87 and a beta of 1.24. AtriCure, Inc. has a twelve month low of $25.36 and a twelve month high of $43.18. The company has a 50-day moving average price of $30.05 and a two-hundred day moving average price of $31.36.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The firm had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.37% and a net margin of 1.85%.During the same period last year, the company earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities analysts forecast that AtriCure, Inc. will post 0.13 EPS for the current year.

More AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: Q2 earnings of $0.18 per share beat the $0.03 consensus and improved from a loss a year ago, showing a meaningful profitability turnaround. AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Revenue of $153.6 million topped Wall Street estimates of $151.8 million, reinforcing that demand remains solid. AtriCure Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company lifted FY2026 EPS guidance to $0.24-$0.32, well above the prior consensus, and revenue guidance of $602 million-$610 million is also near or slightly above expectations. AtriCure Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management described the quarter as one of “healthy growth” and a “significant step up in profitability,” which supports the recent stock strength. AtriCure Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Short-interest data showed 0 reported shares, so it does not appear to be a meaningful trading catalyst.

Insider Activity

In other news, Director Karen Prange sold 3,000 shares of AtriCure stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $28.65, for a total transaction of $85,950.00. Following the completion of the sale, the director owned 26,373 shares in the company, valued at approximately $755,586.45. This trade represents a 10.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 4.00% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on ATRC. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Weiss Ratings lowered AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 4th. Wall Street Zen cut AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Zacks Research downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 4th. Finally, Raymond James Financial set a $52.00 price target on AtriCure in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, AtriCure presently has an average rating of “Moderate Buy” and an average price target of $49.12.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.